Inventor · disambiguated record
Antje Danielczyk
Also filed as: DANIELCZYK ANTJE
16 granted patents·12 pending applications·88 citations·filing 2003–2025
92Inventor score
Top patents by PatentIndex Score
28 records- 0192US11872289B2Anti-MUC1 antibody-drug conjugateDAIICHI SANKYO CO LTD·Filed 2022·Granted Jan 16, 2024·4 cites·22 claims
- 0289US9845361B2Recognition molecules for the treatment and detection of tumorsGLYCOTOPE GMBH·Filed 2014·Granted Dec 19, 2017·8 cites·7 claims
- 0389US9051356B2Use of human cells of myeloid leukaemia origin for expression of antibodiesGOLETZ STEFFEN·Filed 2007·Granted Jun 9, 2015·11 cites·46 claims
- 0489US9051370B2Humanized EGFR antibodiesGOLETZ STEFFEN·Filed 2011·Granted Jun 9, 2015·9 cites·19 claims
- 0587US10280230B2Use of human cells of myeloid leukemia origin for expression of antibodiesGLYCOTOPE GMBH·Filed 2015·Granted May 7, 2019·5 cites·37 claims
- 0686US8088357B2Tumor-specific recognition moleculesGOLETZ STEFFEN·Filed 2003·Granted Jan 3, 2012·24 cites·6 claims
- 0785US9345794B2Tumor-specific recognition moleculesGLYCOTOPE GMBH·Filed 2013·Granted May 24, 2016·5 cites·22 claims
- 0884US8617846B2Tumor-specific recognition moleculesGOLETZ STEFFEN·Filed 2011·Granted Dec 31, 2013·5 cites·22 claims
- 0983US9359439B2Fab-glycosylated antibodiesGOLETZ STEFFEN·Filed 2011·Granted Jun 7, 2016·6 cites·11 claims
- 1082US12291577B2Anti-MUC1 antibody-drug conjugateDAIICHI SANKYO CO LTD·Filed 2023·Granted May 6, 2025·0 cites·30 claims
- 1181US9217038B2MUC1 antibodiesGOLETZ STEFFEN·Filed 2010·Granted Dec 22, 2015·6 cites·18 claims
- 1280US8779102B2Recognition molecules for the treatment and detection of tumorsGOLETZ STEFFEN·Filed 2004·Granted Jul 15, 2014·5 cites·37 claims
- 1376US2025223375A1Anti-muc1 antibody-drug conjugateDAIICHI SANKYO CO LTD·Filed 2025·Application pending·0 cites
- 1474US2025257149A1Anti-muc1 antibodyGLYCOTOPE GMBH·Filed 2025·Application pending·0 cites
- 1567US12479926B2Anti-MUC1 antibody-drug conjugateDAIICHI SANKYO CO LTD·Filed 2019·Granted Nov 25, 2025·0 cites·32 claims
- 1667US12297289B2Anti-MUC1 antibodyGLYCOTOPE GMBH·Filed 2019·Granted May 13, 2025·0 cites·37 claims
- 1760US2019359731A1Use of human cells of myeloid leukaemia origin for expression of antibodiesGLYCOTOPE GMBH·Filed 2019·Application pending·0 cites
- 1853US2016068609A1Anti-cancer treatments with anti-egfr antibodies having a low fucosylationGLYCOTOPE GMBH·Filed 2014·Application pending·0 cites
- 1948US2025074999A1Antibodies against lypd3PENTIXAPHARM AG·Filed 2023·Application pending·0 cites
- 2043US2015166664A1Novel therapeutic treatments with anti-her2 antibodies having a low fucosylationGLYCOTOPE GMBH·Filed 2013·Application pending·0 cites
- 2142US12415864B2Humanized antibodies against Lewis YPENTIXAPHARM AG·Filed 2021·Granted Sep 16, 2025·0 cites·18 claims
- 2242US2020087410A1Humanized anti-cd40 antibodiesGLYCOTOPE GMBH·Filed 2018·Application pending·0 cites
- 2341US2021107961A1Fusion Protein Constructs Comprising an Anti-MUC1 Antibody and IL-15GLYCOTOPE GMBH·Filed 2019·Application pending·0 cites
- 2440US2015353959A1Peptides for enhancing protein expressionGLYCOTOPE GMBH·Filed 2014·Application pending·0 cites
- 2537US2020148785A1Pd-l1 and ta-muc1 antibodiesGLYCOTOPE GMBH·Filed 2018·Application pending·0 cites
- 2637US2020131275A1Multispecific antibody constructs binding to muc1 and cd3GLYCOTOPE GMBH·Filed 2018·Application pending·0 cites
- 2735US10184135B2Eukaryotic expression vectors comprising regulatory elements of the globin gene clustersGLYCOTOPE GMBH·Filed 2016·Granted Jan 22, 2019·0 cites·23 claims
- 2835US2018028680A1Glycooptimized antibody drug conjugatesGLYCOTOPE GMBH·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →